Ptc Therapeutics (PTCT) Enterprise Value (2012 - 2026)

Ptc Therapeutics' Enterprise Value history runs 15 years deep, the most recent figure standing at -$1.9 billion for Q1 2026.

• In Q1 2026, Enterprise Value rose 6.65% year-over-year to -$1.9 billion; the TTM figure through Mar 2026 stood at -$1.9 billion (up 6.65% YoY), while the FY2025 annual figure was -$1.9 billion, down 70.69% from the prior year.
• Enterprise Value was -$1.9 billion for Q1 2026 at Ptc Therapeutics, up from -$1.9 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$286.3 million in Q1 2023 to a low of -$2.0 billion in Q1 2025.
• Historically, Enterprise Value has averaged -$1.0 billion across 5 years, with a median of -$884.8 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value surged 66.77% in 2022, then plunged 243.73% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$410.7 million in 2022, then sank by 113.47% to -$876.7 million in 2023, then retreated by 29.99% to -$1.1 billion in 2024, then slumped by 70.69% to -$1.9 billion in 2025, then grew by 2.72% to -$1.9 billion in 2026.
• The last three Enterprise Value figures came in at -$1.9 billion (Q1 2026), -$1.9 billion (Q4 2025), and -$1.7 billion (Q3 2025), per Business Quant data.